13F Pro Quality Score

53.5/100

Rank #1,382 of 2,961 stocksTOP 50%

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Revenue Growth

92.6/100

Profitability

30.4/100

Balance Sheet

18.3/100

Earnings Quality

65.5/100

Free Cash Flow

35.9/100

Institutional Flow

72.6/100

Revenue Scale

67.9/100

Dilution Risk

11.7/100
Email me the moment this company reports earnings
AI Research Report
Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.
Upgrade to Pro
Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

NTRA Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for Natera, Inc. (NTRA), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores NTRA at 53.5/100 on a 32-signal composite quality model, placing it at rank #1,382 of 2,961 stocks — the top half of the AI-ranked universe. NTRA scores in the top quartile across revenue growth (92.6). Areas of concern include balance sheet strength (18.3) and profitability (30.4), which score below median versus the broader universe. Shareholder dilution risk is elevated at 11.7/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Natera, Inc. reports quarterly revenue of $752.8M, net income of $-67.0M, an operating margin of -10.1%. Top institutional holders of NTRA by reported 13-F value include JPMORGAN CHASE, BlackRock, PRICE T ROWE ASSOCIATES, based on the most recent SEC filings. NTRA trades on the Nasdaq exchange and files with the SEC under CIK 1604821. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate NTRA daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Natera, Inc. directly from SEC EDGAR. Natera, Inc.'s 13F Pro composite quality score has ranged between 30 and 54 since 2021, currently 53.5 — an improving long-term trajectory across 68 quarterly and live scoring snapshots.

Fun facts about Natera, Inc.

Quirks, history, and lore behind NTRA — the kind of stuff that makes a stock memorable.

  • 1
    The Basics
    U.S. healthcare company · listed on Nasdaq · headquartered in Texas · focused on genetic testing.
  • 2
    The Numbers
    Annual revenue in the roughly $1 billion range and growing fast, though it has historically operated at a net loss while scaling its lab network.
  • 3
    The History
    Founded around 2004 and built on technology spun out of Stanford University, it went public on Nasdaq and has steadily expanded beyond its original research roots.
  • 4
    The Secret
    Its core business is cell-free DNA analysis — fishing tiny fragments of genetic material out of a blood draw to catch problems before symptoms ever appear.
  • 5
    The Lore
    Its flagship Panorama test screens pregnant women for chromosomal conditions like Down syndrome without a needle anywhere near the baby — a genuine paradigm shift in prenatal care.
  • 6
    The Giveaway
    The go-to name in non-invasive prenatal testing (NIPT), it also runs oncology liquid biopsy and hereditary cancer panels — making it the closest thing to a genetic early-warning system for the whole human body.
▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q2 2026

$752.8M

Net Income

Q2 2026

$-67.0M

Free Cash Flow

Q2 2026

$-8.6M

Operating Margin

Q2 2026

-10.1%

ROIC

Q2 2026

-15.9%

D/E Ratio

Q2 2026

0.04

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

+35.9% YoY
$2.31BFY 2025
FY22 $820.2MFY23 $1.08BFY24 $1.70BFY25 $2.31B

Net Income

-9.3% YoY
$-208.2MFY 2025
FY22 $-547.8MFY23 $-434.8MFY24 $-190.4MFY25 $-208.2M

Operating Income

-39.4% YoY
$-309.9MFY 2025
FY22 $-541.0MFY23 $-446.2MFY24 $-222.3MFY25 $-309.9M

EPS (Diluted)

+0.7% YoY
$-1.52FY 2025
FY22 $-5.57FY23 $-3.78FY24 $-1.53FY25 $-1.52

Total Assets

+44.4% YoY
$2.40BFY 2025
FY22 $1.39BFY23 $1.44BFY24 $1.66BFY25 $2.40B

Total Debt

-0.0% YoY
$80.3MFY 2025
FY22 $362.0MFY23 $363.3MFY24 $80.4MFY25 $80.3M

Op. Cash Flow

+58.7% YoY
$215.3MFY 2025
FY22 $-431.5MFY23 $-247.0MFY24 $135.7MFY25 $215.3M

Free Cash Flow

+57.6% YoY
$109.1MFY 2025
FY22 $-479.2MFY23 $-286.2MFY24 $69.2MFY25 $109.1M

Get alerted when NTRA's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Natera, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)
XBRL financial facts (revenue, EPS, margins)
Insider transactions (Form 4)
Institutional 13F holdings
Quality rankings (32 signals)
AI analyst debates & daily meetings
Historical financial trends
Peer comparison & sector analysis

Top Institutional Holders of NTRA

Companies Similar to NTRA

Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.

INSM

INSMED Inc

38
AI score
Very similar · 33 shared holders
AXSM

Axsome Therapeutics, Inc.

42
AI score
Similar quality profile · 16 shared holders
GH

Guardant Health, Inc.

39
AI score
Similar quality profile · 27 shared holders
ADPT

Adaptive Biotechnologies Corp

39
AI score
Similar quality profile · 15 shared holders
GKOS

GLAUKOS Corp

41
AI score
Similar quality profile · 17 shared holders
ARWR

ARROWHEAD PHARMACEUTICALS, INC.

42
AI score
Similar quality profile · 9 shared holders
HIMS

Hims & Hers Health, Inc.

52
AI score
Similar quality profile · 3 shared holders
COO

COOPER COMPANIES, INC.

58
AI score
Similar quality profile · 21 shared holders

Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.

Put NTRA on your watchlist

Track score changes the day Natera, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Is NTRA a good stock to buy?

13F Pro's AI-powered analysis of Natera, Inc. (NTRA) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for NTRA are available on the NTRA stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. NTRA is classified as a large company.

Which hedge funds own NTRA?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling NTRA. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Natera, Inc.'s investment landscape.